Ómar Vesga

1.7k total citations
34 papers, 1.3k citations indexed

About

Ómar Vesga is a scholar working on Pharmacology, Infectious Diseases and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ómar Vesga has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 16 papers in Infectious Diseases and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ómar Vesga's work include Antibiotics Pharmacokinetics and Efficacy (20 papers), Antimicrobial Resistance in Staphylococcus (14 papers) and Pharmaceutical studies and practices (8 papers). Ómar Vesga is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (20 papers), Antimicrobial Resistance in Staphylococcus (14 papers) and Pharmaceutical studies and practices (8 papers). Ómar Vesga collaborates with scholars based in Colombia, United States and Netherlands. Ómar Vesga's co-authors include Andrés F. Zuluaga, María Agudelo, Carlos A. Rodríguez, Richard A. Proctor, David R. Andes, William A. Craig, James M Balwit, R S Hare, C. Hardalo and George L. Drusano and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Ómar Vesga

34 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ómar Vesga Colombia 17 529 432 356 272 257 34 1.3k
Paul M. Beringer United States 22 500 0.9× 333 0.8× 286 0.8× 362 1.3× 175 0.7× 64 1.4k
Paul R. Ingram Australia 21 355 0.7× 393 0.9× 376 1.1× 396 1.5× 196 0.8× 61 1.4k
Laurent Massias France 26 562 1.1× 588 1.4× 534 1.5× 567 2.1× 291 1.1× 71 1.8k
Jerina Boelens Belgium 20 262 0.5× 487 1.1× 181 0.5× 734 2.7× 279 1.1× 83 1.8k
J. Blaser Switzerland 21 995 1.9× 363 0.8× 654 1.8× 544 2.0× 156 0.6× 51 1.6k
Medini K. Annavajhala United States 20 231 0.4× 587 1.4× 619 1.7× 244 0.9× 503 2.0× 47 1.9k
Wentao Ni China 21 424 0.8× 709 1.6× 678 1.9× 355 1.3× 338 1.3× 47 2.0k
John Mohr United States 21 378 0.7× 721 1.7× 287 0.8× 472 1.7× 234 0.9× 49 1.5k
Lavern M. Vercaigne Canada 20 700 1.3× 297 0.7× 481 1.4× 625 2.3× 247 1.0× 40 1.7k
Min‐Chi Lu Taiwan 28 200 0.4× 446 1.0× 756 2.1× 343 1.3× 525 2.0× 81 1.8k

Countries citing papers authored by Ómar Vesga

Since Specialization
Citations

This map shows the geographic impact of Ómar Vesga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ómar Vesga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ómar Vesga more than expected).

Fields of papers citing papers by Ómar Vesga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ómar Vesga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ómar Vesga. The network helps show where Ómar Vesga may publish in the future.

Co-authorship network of co-authors of Ómar Vesga

This figure shows the co-authorship network connecting the top 25 collaborators of Ómar Vesga. A scholar is included among the top collaborators of Ómar Vesga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ómar Vesga. Ómar Vesga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vesga, Ómar, et al.. (2021). Highly sensitive scent-detection of COVID-19 patients in vivo by trained dogs. PLoS ONE. 16(9). e0257474–e0257474. 15 indexed citations
2.
Rodríguez, Carlos A., et al.. (2020). A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. PLoS ONE. 15(12). e0243365–e0243365. 7 indexed citations
3.
Agudelo, María, Carlos A. Rodríguez, Andrés F. Zuluaga, & Ómar Vesga. (2019). Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin. PLoS ONE. 14(2). e0211096–e0211096. 3 indexed citations
4.
5.
Rodríguez, Carlos A., et al.. (2016). Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam. PLoS ONE. 11(5). e0155806–e0155806. 9 indexed citations
6.
Rodríguez, Carlos A., María Agudelo, Andrés F. Zuluaga, & Ómar Vesga. (2016). In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products. International Journal of Antimicrobial Agents. 49(2). 189–197. 18 indexed citations
7.
González, Javier, Carlos A. Rodríguez, María Agudelo, Andrés F. Zuluaga, & Ómar Vesga. (2016). Antifungal pharmacodynamics: Latin America's perspective. The Brazilian Journal of Infectious Diseases. 21(1). 79–87. 8 indexed citations
8.
González, Javier, Carlos A. Rodríguez, Andrés F. Zuluaga, María Agudelo, & Ómar Vesga. (2015). Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis. PLoS ONE. 10(11). e0141872–e0141872. 2 indexed citations
9.
Zuluaga, Andrés F., Carlos A. Rodríguez, María Agudelo, & Ómar Vesga. (2015). Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model. BMC Research Notes. 8(1). 546–546. 2 indexed citations
10.
Vesga, Ómar, et al.. (2010). Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator. Antimicrobial Agents and Chemotherapy. 54(8). 3271–3279. 67 indexed citations
11.
Rodríguez, Carlos A., María Agudelo, Andrés F. Zuluaga, & Ómar Vesga. (2010). In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin. BMC Infectious Diseases. 10(1). 153–153. 34 indexed citations
12.
Zuluaga, Andrés F., et al.. (2010). Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model. PLoS ONE. 5(5). e10744–e10744. 34 indexed citations
13.
Zuluaga, Andrés F., María Agudelo, Carlos A. Rodríguez, & Ómar Vesga. (2009). Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. PubMed. 9(1). 1–1. 86 indexed citations
14.
15.
Restrepo, Andrea, et al.. (2005). Optimization of culture conditions to obtain maximal growth of penicillin-resistant Streptococcus pneumoniae. BMC Microbiology. 5(1). 34–34. 23 indexed citations
16.
Zuluaga, Andrés F., et al.. (2003). FOUNDATION OF A FUNCTIONAL MURINE PATHOGEN FREE ANIMAL FACILITY IN COLOMBIA. IATREIA. 16(2). 115–131. 1 indexed citations
17.
Agudelo, María, et al.. (2003). Fundación del primer bioterio MPF funcional de Colombia. IATREIA. 2 indexed citations
18.
Vesga, Ómar, et al.. (1996). Pharmacodynamic activity of BAY 12-8039 in animal infection models. 36. 103. 3 indexed citations
19.
Vesga, Ómar, et al.. (1996). Staphylococcus aureus Small Colony Variants Are Induced by the Endothelial Cell Intracellular Milieu. The Journal of Infectious Diseases. 173(3). 739–742. 138 indexed citations
20.
Proctor, Richard A., James M Balwit, & Ómar Vesga. (1994). Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections.. PubMed. 3(6). 302–12. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul M. Beringer Breakdown of academic impact, for papers by Paul R. Ingram Breakdown of academic impact, for papers by Laurent Massias Breakdown of academic impact, for papers by Jerina Boelens Breakdown of academic impact, for papers by J. Blaser Breakdown of academic impact, for papers by Medini K. Annavajhala Breakdown of academic impact, for papers by Wentao Ni Breakdown of academic impact, for papers by John Mohr Breakdown of academic impact, for papers by Lavern M. Vercaigne Breakdown of academic impact, for papers by Min‐Chi Lu
Rankless by CCL
2026